Drug intelligence / Profile preview

XBH111

Development stage: Preclinical
Lead developer: Shanghai XBH Biotechnology
Modality: T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

XBH111 is a preclinical-stage therapeutic candidate developed by GV20 Oncotherapy for the treatment of solid tumors. It utilizes a dual-modality platform, functioning as both an antibody-drug conjugate (ADC) and a T-cell engager. This design is intended to provide a multi-pronged attack on cancer cells by delivering a cytotoxic payload directly to the tumor while simultaneously redirecting and activating T cells to eliminate the malignant cells. The specific molecular targets for XBH111 have not been publicly disclosed.

Beyond the preview

Go deeper on XBH111.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XBH111.

Explore the full profile